10 results about "Leukotriene" patented technology

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.

The invention belongs to the crossing field of traditional Chinese medicine modernization and biotechnology, and particularly relates to application of a metabolic marker in preparation of a product for auxiliary diagnosis of retinal vein occlusion (RVO) or evaluation of prognosis of treatment of RVO by ginseng-wolfberry omentum granules. The metabolic marker is selected from at least one of the following metabolites: leukotriene B4, (R)-2-feruloyl-1-(4-hydroxyphenyl)-1, 2-ethylene glycol, hyoscyamine base A6, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxy-5, 6, 7, 8, 9, 10, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxyl-5, 6, 7, 8, 10-tetrahydroxyl-5, 7, 8, 10 The invention relates to an anti-inflammatory agent which is prepared from 5, 5 '-diisopropyl-2, 2'-dimethyl biphenyl (3, 3 ', 4, 4', 1-ethyl piperidine, flavin mononucleotide, crystal orchid glycoside, 2-O-caffeoyl arbutin, dimethyl ellagic acid glucuronide, 4 '-hydroxy-3, 4, 5-resveratrol trimethyl ether, 3'-methoxy petamicin, phenylalanyl-leucyl-isoleucyl-tyrosine and dihydroferulic acid-4-sulfate.

The present application provides the use of leukotrienes in inducing stem cells to differentiate into hematopoietic stem / progenitor cells and the application thereof. According to specific embodiments of the present application, the addition of appropriate amounts of leukotrienes during the process of inducing stem cells to differentiate into hematopoietic stem / progenitor cells can significantly improve the differentiation efficiency of the stem cells into hematopoietic stem / progenitor cells, and significantly increase the number of erythroid cells, megakaryocytic cells, granulocytic cells and mononuclear cells obtained after the differentiation of the stem cells through hematopoietic stem / progenitor cells.

Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

The invention discloses a biomarker for auxiliary diagnosis or evaluation of epilepsy related to nodular sclerosis and application of the biomarker. The biomarker comprises any one or a combination of at least two of a complement component 7, N-acetylgalactosamine transferase 3, an ecological virus integration site 5, a hemoglobin subunit theta 1 or leukotriene A4 hydrolase. The invention provides a protein biomarker combination which is low in invasiveness and easy to quantify and can be used for preoperative evaluation, postoperative prognosis judgment and curative effect monitoring and a detection method thereof, and the accuracy and reliability of nodular sclerosis related epilepsy diagnosis and risk evaluation are remarkably improved.

This invention belongs to the field of animal model analysis technology, specifically relating to a method for establishing a model of gouty rheumatic fever subtypes, the application of a biomarker group, and a detection method. This invention constructs two subtype models of gouty rheumatic fever with more emphasis on dampness and fever with more emphasis on dampness, and establishes a UPLC-MS detection method for serum biomarkers, obtaining a biomarker group including lauroylcarnitine, taurine, palmitoyl-L-carnitine, L-leucine, leukotriene A4, and 13-Oxo-9,11-tridecadienoic acid. Studies show that this biomarker group can simply and effectively distinguish between gouty rheumatic fever with more emphasis on dampness and fever with more emphasis on dampness, and determine the success of model establishment for the two subtypes. Therefore, it can replace conventional characterization and biochemical pathological evaluation methods, improving the objectivity and operability of the assessment.

The present invention addresses the problem of providing a novel cyclic amine derivative or a pharmaceutically acceptable salt or hydrate thereof, and a medicine containing the compound as an active ingredient.　The cyclic amine derivative or a pharmaceutically acceptable salt or hydrate thereof according to the present invention has both an antagonistic effect on histamine and an antagonistic effect on leukotrienes, and is therefore very useful as an active ingredient of a pharmaceutical composition such as a prophylactic and / or therapeutic agent for a wide range of allergic diseases.

The invention belongs to the technical field of chemical material engineering, and particularly relates to a vascularization promoting coating and application thereof in a drainage tube. And the vascularization promoting coating comprises linoleic acid and leukotriene D4. The main body material of the drainage tube is PPDO and barium sulfate, and the drainage tube is coated with a PAA hydrogel coating loaded with linoleic acid and leukotriene D4. The PAA hydrogel coating has a pH response mechanism, can intelligently release linoleic acid and leukotriene D4 according to the change of a tissue recovery environment after a pancreatic cancer operation, and promotes vascularization. The biodegradability of the PPDO material reduces the necessity that a patient takes out the drainage tube after a second operation, barium sulfate is used as a developing agent, the degradation condition of the drainage tube can be observed in real time, and the safety and effectiveness of the operation are improved.

The invention discloses an application of amentotaxus biflavone in preparation of a medicine for treating viral sepsis, the amentotaxus biflavone has high affinity to two targets of leukotriene A4 hydrolase (LTA4H) and leukotriene B4 Receptor 1 (Leukotriene B4 Receptor 1, BLT1), can simultaneously inhibit the activity of the LTA4H and the BLT1, and can be used for preparing a medicine for treating the viral sepsis, so that the amentotaxus biflavone can be used for preparing a medicine for treating the viral sepsis. According to the present invention, the virus infection is blocked, the generation of the inflammatory mediator leukotriene B4 mediated by LTA4H is blocked, the inflammatory reaction is amplified by BLT1, the survival rate of the influenza virus infected sepsis mouse model is improved, and the application can be used for preparing the drug for treating viral sepsis.

This invention proposes the use of leukotrienes in promoting the maturation of erythroid cells. According to a specific embodiment of the invention, adding an appropriate amount of leukotrienes during the induction of erythroid cell maturation can effectively promote the maturation of the erythroid cells.